{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:29:08Z","timestamp":1783434548729,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["20FC1030"],"award-info":[{"award-number":["20FC1030"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clineuro.2022.107371","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T23:06:26Z","timestamp":1658185586000},"page":"107371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Serum pentraxin 3 concentration correlates with disease severity in patients with myasthenia gravis"],"prefix":"10.1016","volume":"220","author":[{"given":"Yuta","family":"Kojima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manato","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Akamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Himuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ichi","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2022.107371_bib1","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clineuro.2022.107371_bib2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/cei.12272","article-title":"Serum cytokine and chemokine profiles in patients with myasthenia gravis","volume":"176","author":"Uzawa","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clineuro.2022.107371_bib3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/jnnp-2014-309232","article-title":"Serum high mobility group box 1 is upregulated in myasthenia gravis","volume":"86","author":"Uzawa","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2022.107371_bib4","doi-asserted-by":"crossref","first-page":"25886","DOI":"10.1038\/srep25886","article-title":"Changes in inflammatory cytokine networks in myasthenia gravis","volume":"6","author":"Uzawa","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clineuro.2022.107371_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/cei.13499","article-title":"Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study","volume":"202","author":"Uzawa","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clineuro.2022.107371_bib6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1084\/jem.153.4.977","article-title":"Hamster female protein. A new Pentraxin structurally and functionally similar to C-reactive protein and amyloid P component","volume":"153","author":"Coe","year":"1981","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.clineuro.2022.107371_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102584","article-title":"Pentraxin 3: A promising therapeutic target for autoimmune diseases","volume":"19","author":"Wu","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clineuro.2022.107371_bib8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1084\/jem.20061301","article-title":"The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps","volume":"204","author":"Jaillon","year":"2007","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.clineuro.2022.107371_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/acr.20094","article-title":"Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease","volume":"62","author":"Hollan","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clineuro.2022.107371_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12016-015-8476-9","article-title":"PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis","volume":"49","author":"Bassi","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.clineuro.2022.107371_bib11","doi-asserted-by":"crossref","DOI":"10.3109\/08916934.2014.983264","article-title":"Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus","volume":"48","author":"Cie\u015blik","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clineuro.2022.107371_bib12","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3899\/jrheum.080343","article-title":"Increased serum pentraxin 3 in patients with systemic sclerosis","volume":"36","author":"Iwata","year":"2009","journal-title":"J. Rheuma"},{"key":"10.1016\/j.clineuro.2022.107371_bib13","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1007\/s10620-007-0075-z","article-title":"Increased expression of long pentraxin PTX3 in inflammatory bowel diseases","volume":"53","author":"Kato","year":"2008","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.clineuro.2022.107371_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2022.107371_bib15","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2022.107371_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/cen3.12091","article-title":"Clinical features and treatment status of adult myasthenia gravis in Japan","volume":"5","author":"Murai","year":"2014","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.clineuro.2022.107371_bib17","doi-asserted-by":"crossref","first-page":"8303","DOI":"10.4049\/jimmunol.175.12.8303","article-title":"TNFalpha-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK","volume":"175","author":"Han","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.clineuro.2022.107371_bib18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1189\/jlb.0905493","article-title":"Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL-10 and inhibition by IFN-gamma","volume":"79","author":"Doni","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.clineuro.2022.107371_bib19","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/immu.200310022","article-title":"Biochemical and functional characterization of the interaction between pentraxin 3 and C1q","volume":"33","author":"Nauta","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clineuro.2022.107371_bib20","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.immuni.2011.08.011","article-title":"Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells","volume":"35","author":"Griffith","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.clineuro.2022.107371_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3389\/fimmu.2014.00354","article-title":"Impaired clearance of apoptotic cells in chronic inflammatory diseases: therapeutic implications","volume":"5","author":"Szondy","year":"2014","journal-title":"Front Immunol."},{"key":"10.1016\/j.clineuro.2022.107371_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.arcmed.2016.05.006","article-title":"Association of pentraxin 3 with autoimmune diseases: a systematic review and meta-analysis","volume":"47","author":"Huang","year":"2016","journal-title":"Arch. Med Res"},{"key":"10.1016\/j.clineuro.2022.107371_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2015.06.011","article-title":"Elevated plasma interleukin-17A in a subgroup of Myasthenia Gravis patients","volume":"78","author":"Xie","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.clineuro.2022.107371_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-3083.2012.02703.x","article-title":"T helper type 17 cells expand in patients with myasthenia-associated thymoma","volume":"76","author":"Wang","year":"2012","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.clineuro.2022.107371_bib25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10875-012-9685-0","article-title":"Changes of Treg-associated molecules on CD4+CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants","volume":"32","author":"Xu","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clineuro.2022.107371_bib26","article-title":"Intrathymic Tfh\/B Cells Interaction Leads to Ectopic GCs Formation and Anti-AChR Antibody Production: Central Role in Triggering MG Occurrence","volume":"53","author":"Zhang","year":"2016","journal-title":"Mol. Neurobiol."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846722002529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846722002529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:42:46Z","timestamp":1759588966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846722002529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":26,"alternative-id":["S0303846722002529"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2022.107371","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum pentraxin 3 concentration correlates with disease severity in patients with myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2022.107371","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107371"}}